secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2022-02-23T23:59:59+00:00
Accession:  0000950170-22-001777
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences reports Q4 net income of $279.4M on Gilead option exercise; cash ~$1.4B post-Gilead payments
--------------------------------------------------------------------------------

- Q4 2021 revenue $354.5M (vs $9.5M Q4 2020) primarily from Gilead license revenue; full-year revenue $382.9M.
- Net income Q4 $279.4M vs net loss $51.9M prior year; full-year net income $52.8M vs net loss $122.9M.
- Cash, equivalents and investments $681.3M at Dec 31, 2021; plus $725M from Gilead in Jan 2022 = ~$1.4B, funding into 2026.
- First patient dosed in PACIFIC-8 Phase 3 (domvanalimab + durvalumab in Stage 3 NSCLC); two more Phase 3 studies planned for 2022.
- Data readouts for ARC-7 (domvanalimab/etrumadenant in NSCLC) and ARC-8 (quemliclustat in pancreatic cancer) expected 2H22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022001777/0000950170-22-001777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017022001777/rcus-20220223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer